We assessed the diagnostic accuracy of cerebrospinal fluid (CSF) neurofilament light chain (NFL) protein in the classification of patients with Alzheimer's disease (AD) and cognitively healthy control individuals (HCs) and patients with frontotemporal dementia (FTD) as comparisons. Particularly, we tested the performance of CSF NFL concentration in differentiating patient groups stratified by fluid biomarker profiles, independently of the severity of cognitive impairment (mild cognitive impairment (MCI) and AD dementia individuals), using a biomarker-guided descriptive classification system for AD. CSF NFL concentrations were examined in a multicenter cross-sectional study of 108 participants stratified in AD pathophysiology-negative (both CSF tau and the 42-amino acid-long amyloid-beta (Ab) peptide (Ab 1-42 )) (n ¼ 15), tau pathology-positive only (n ¼ 15), Ab pathology-positive only (n ¼ 13), AD pathophysiologypositive (n ¼ 33), FTD (n ¼ 9) patients, and HCs (n ¼ 23), according to the biomarker-based classification system. The performance of CSF NFL in discriminating AD pathophysiology-positive patients from HCs is fair, whereas the ability in differentiating tau-positive patients from HCs is poor. The classificatory performance in distinguishing AD pathophysiology-positive patients from FTD is unsatisfactory.
Introduction
The canonical pathophysiological hallmarks of Alzheimer's disease (AD) are a) extracellular deposition of aggregated amyloid beta (Ab) into amyloid plaques, and b) intraneuronal accumulation of neurofibrillary tangles (Hyman et al., 2012) . Neurofilaments are neuron-specific heteropolymers that act as key structural components of the neuronal cytoskeleton (Lee et al., 1993) and are mostly expressed in large-caliber myelinated axons (Liu et al., 2004) . One specific neurofilament subunit, the neurofilament light chain (NFL) protein, is currently being examined as a candidate biomarker for the diagnosis of neurodegenerative diseases (Landqvist Wald€ o et al., 2013; Olsson et al., 2016; Scherling et al., 2014; Zetterberg et al., 2016) . AD brains are characterized by a positive immunohistochemical expression of NFL (Nakamura et al., 1997) , which undergoes significant hyperphosphorylation and accumulation (Wang et al., 2001) . In addition, a decrease of NFL in the occipital cortex of AD patients has been reported, potentially reflecting the extent of neuronal loss (Bajo et al., 2001) . In recent years, increased cerebrospinal fluid (CSF) concentrations of NFL (CSF NFL) have been detected in both AD dementia (Olsson et al., 2016; Zetterberg et al., 2016) and frontotemporal dementia (FTD) (Landqvist Wald€ o et al., 2013; Scherling et al., 2014) compared with healthy controls (HCs), with CSF NFL reported to be higher in FTD than in AD dementia patients (Sj€ ogren et al., 2000) . Increased CSF NFL has been reported to have significant effect sizes when differentiating between HCs and patients with AD, thus highlighting an association with AD, as recently shown in a large meta-analysis (Olsson et al., 2016) . Moreover, NFL e in both CSF and serum e has been found to be a candidate biomarker for clinical disease onset and severity and to have a prognostic value in genetic FTD (Meeter et al., 2016; Olsson et al., 2016) .
The aim of this study was to assess the ability of CSF NFL to discriminate groups of cognitively impaired patients stratified across an AD pathophysiology spectrum using the newly established classification system, i.e. independently of the degree of cognitive impairment (Jack et al., 2016) : in this regard, mild cognitive impairment (MCI) and AD dementia individuals were grouped into a single category. The "A/T/N" scheme employs three binary biomarker categories which reflect AD pathophysiology, where "A" refers to "amyloid-beta (Ab) pathology", "T" to "tau pathology", and "N" to neurodegeneration. Specifically, we evaluated the performance of NFL in distinguishing patients with AD pathophysiology e i.e. showing decreased CSF concentrations of the 42-amino acid-long Ab peptide (Ab 1-42 ) and increased CSF concentrations of total tau (t-tau) or hyperphosphorylated tau (ptau) (Dubois et al., 2014) e as well as patients with evidence of tau pathology only and cognitively HCs. Furthermore, in order to evaluate the ability of CSF NFL to differentiate AD pathophysiology from other neurodegenerative diseases, we integrated a group of FTD patients as comparisons with another clinically relevant agerelated neurodegenerative disease.
Methods

Study participants
This research was designed as a multicenter cross-sectional study conducted retrospectively in a convenience series from three independent European academic memory clinic centers. A total of 135 participants were examined; out of these individuals, 27 were excluded due to missing data in one or more CSF biomarkers. The remaining 108 were included in the present study: 35 participants were recruited from the Institute of Memory and Alzheimer's Disease (Institut de la M emoire et de la Maladie d'Alzheimer, IM2A) at Piti e-Salpêtri ere University Hospital in Paris (France), 57 from the German Center for Neurodegenerative Diseases (DZNE) in Rostock (Germany), and 16 from the Institute of Neuroscience and Physiology at Sahlgrenska University Hospital in M€ olndal (Sweden).
The study was conducted in accordance with the tenets of the Declaration of Helsinki and approved by the local Ethical Committees at each participating university center. All participants or their representatives gave written informed consent for the use of their clinical data for research purposes.
Cohort stratification and biomarker assessment
Patients received either a) a clinical diagnosis of AD dementia according to the National Institute of Neurological and Communicative Disorders and StrokeeAlzheimer's Disease and Related Disorders Association (NINCDSeADRDA) consensus criteria (McKhann et al., 1984) , b) a clinical diagnosis of MCI according to the MCI core clinical criteria of the National Institute on Aging-Alzheimer's Association (NIA-AA) guidelines (Albert et al., 2011) , or c) a diagnosis of FTD following the consensus on clinical diagnostic criteria of 1998 (Neary et al., 1998) . Cognitively HCs were individuals who volunteered for a lumbar puncture. Inclusion criteria were the absence of neurological/psychiatric disease history and a MiniMental State Examination (MMSE) score between 27 and 30. Our population was dissected according to the A/T/N scheme, a biomarker-based descriptive classification system recently proposed (Baldacci et al., 2016; Jack et al., 2016) . The detailed description of the cohort stratification according to the A/T/N scheme, CSF sampling, immunoassays for both CSF core biomarkers (Ab 1-42 , t-tau, and p-tau) and CSF NFL protein, as well as statistical analysis are reported in the Supplementary Materials.
Statistical analysis
Age-, sex-, and site-adjusted NFL values were compared across groups through nonparametric statistics, after which areas under the receiver operating characteristic curves (AUROCs) for all binary classification problems were computed through logistic regression within a Leave-One-Out Cross-Validation (LOO-CV) approach. The discriminatory ability of NFL to correctly allocate participants to groups was categorized as follows: "excellent" (AUROC 0.90e1.00), "good" (AUROC 0.80e0.89), "fair" (AUROC 0.70e0.79), "poor" (AUROC 0.60e0.69), or "fail"/no discriminatory capacity (AUROC 0.50e0.59) (Xia et al., 2013) . Table 1 (Fig. 1A) . CSF NFL differentiated cognitively HCs from Group 3 and Group 5 with AUROCs ¼ 0.69 (95% CI, 0.50e0.87) (Fig. 1B) and 0.77 (95% CI, 0.64e0.89) (Fig. 1C) , respectively. CSF NFL distinguished between Group 5 and Group 6 (FTD) with AUROC ¼ 0.54 (95% CI, 0.28e0.80) (Fig. 1D) . Equivalent results obtained when stratifying according to purely clinical diagnostic criteria are reported in the Supplementary Materials.
Results
CSF NFL did not improve the diagnostic accuracy provided by core biomarkers (data not shown). Also, the performance of CSF NFL in differentiating cognitively HCs from tau-positive only (Group 3) patients and AD pathophysiology-positive (Group 5) patients was barely fair/poor and fair, respectively.
Discussion
These findings confirm the link between NFL and the neuronal injury marker tau (Olsson et al., 2016; Zetterberg et al., 2016) . Notably, NFL is primarily expressed in large-caliber myelinated axons (Schlaepfer and Lynch, 1977) , and is therefore assumed to be a biomarker of white matter alterations. Increased CSF NFL concentrations are associated with white matter change and other varieties of lesions in subcortical brain areas (Sj€ ogren et al., 2001) . Moreover, a longitudinal study found that CSF NFL concentrations are higher in AD and MCI with respect to HCs, and that CSF NFL concentrations correlate with structural brain alterations and cognitive decline over time . This indicates that CSF NFL may be a progression marker to AD dementia in subjects with MCI and suggests that large-caliber axonal disintegration may be a prominent aspect of AD pathophysiology . This was further substantiated in a recent comprehensive meta-analysis (Olsson et al., 2016) .
In addition, CSF NFL concentration observed in all tau-positive patient categories was higher than in Ab pathology-positive patients. This result is supported by a pivotal study showing similar concentrations of CSF NFL in Ab 1-42 -negative and Ab 1-42 -positive individuals, as dichotomized by a cut-off value (CSF Ab 1-42 < 192 pg/ mL). Consequently, alterations in CSF NFL concentrations do not seem to be dependent on the amyloidogenic Ab 1-42 peptide since they are substantially correlated with biomarkers of neurodegeneration, such as brain atrophy, and cognitive decline .
In contrast to some previous studies (Landqvist Wald€ o et al., 2013; Sj€ ogren et al., 2000) , the ability of CSF NFL to discriminate between AD pathophysiology-positive patients and FTD was unsatisfactory (Fig. 1D ). Additional studies with large patient comparison cohorts across a range of clinically relevant different agerelated neurodegenerative diseases are needed to clarify the true value for differential diagnosis. One possible explanation may be that FTD patients included in the previous studies (Landqvist Wald€ o et al., 2013; Sj€ ogren et al., 2000) were at more advanced disease stages, since CSF NFL concentrations in FTD have been found to reflect disease severity, with higher concentrations related to more severe symptoms and brain atrophy (Scherling et al., 2014) .
The study has some potential caveats that we want to address. Due to the relatively small sample size, it was not feasible to stratify the cohort into all groups established by the original A/T/N scheme (Jack et al., 2016) . The categorization of our cohort was only based on CSF biomarkers, that is, the A/T/N system was utilized without considering additional information derived from neuroimaging modalities, including amyloid-positron emission tomography (amyloid-PET), tau-PET, 18 F-fluorodeoxyglucose-PET ( 18 F-FDG-PET), and structural magnetic resonance imaging (MRI). Therefore, given that only validated core CSF biomarkers (i.e. no neuroimaging) were employed, MCI and AD dementia individuals were grouped into a single category (Fig. S1) . Because of the cross-sectional nature of the study, it was not possible to differentiate potentially stable-MCI subjects from those converting into dementia as well as to report on prognosis and rate of progression of cognitive impairment. Moreover, psychometric data were not available, thus preventing the study of CSF NFL concentrations in relation to different cognitive measures. Additionally, the quantification of the core CSF Table 1 Summary of the demographic, clinical, and biomarker data of the cohort dissected according to the A/T/N classification scheme.
Group 1 HCs Group 2 [A-T-N-]
Group 3 biomarkers of AD was not performed in one reference laboratory and, while we controlled for center effects in our statistical analysis, further inter-laboratory variability cannot be entirely ruled out. It could be also argued that we relied on a commercial research-grade ELISA kit for measuring CSF NFL. The antibodies used in the ELISA have been extensively validated; they were raised against the rod (mid) domain of NFL and are highly sensitive and specific for conformational epitopes in this region of the protein (Norgren et al., 2002) . The best performing antibodies were combined to develop the now commercially available ELISA, as previously described (Norgren et al., 2003) . Another limitation of our study is represented by the relatively small number of patients, especially in the FTD category. Future research efforts should be directed towards increasing statistical power by collecting larger, multi-site cohorts of patients for which CSF data are available. All NFL data were adjusted for age, sex, and site using nonparametric regression. We openly acknowledge that CSF NFL did not add further diagnostic value compared with the core AD biomarkers. Publication bias from preferential reporting of positive findings is well-recognized in biomarker research. These biases inflate the potential clinical validity and utility of published biomarkers while negative results often remain unpublished. Although our study is clearly negative, it may represent a valid addition to the current literature on NFL in neurodegenerative diseases. This pilot study is largely exploratory and is a first attempt to employ NFL protein as a CSF biological marker for the diagnosis of AD by employing a biomarker-based system of classification (Jack et al., 2016) . Conceptually, the A/T/N dissection model addresses the need for a unifying approach to using biomarkers in the study of AD. Due to its nature, the A/T/N scheme represents a flexible model that could be employed in any framework of existing diagnostic criteria (Jack et al., 2016) . Potentially, it is expected to integrate key and novel evolving biomarkers of other relevant pathophysiological mechanisms (Baldacci et al., 2017) belonging to the dimensional spectrum of age-related neurodegenerative diseases, as well as genetic or epigenetic factors.
Conclusion
In summary, our multicenter cross-sectional study highlights the performance of CSF NFL protein in differentiating AD pathophysiology-positive patients from HCs using an innovative classification system that allows a biomarker-driven stratification of patients and is independent of severity of cognitive impairment. From a translational viewpoint, such a dissection model may serve to accurately stratify cohorts of patients according to AD-related pathophysiological pathways. This might represent an optimized basis to develop and improve effective targeted therapeutic interventions for the efficient treatment of the individual patient.
Additional studies are required to examine whether CSF NFL may be employed as a biological indicator of mechanism of action and/or target engagement or as a marker predicting progression of cognitive impairment in drug development studies.
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